Daiichi Co. Ltd. (7643.TO) Japan Half-Year Ended March 31 PARENT 2025 2024 Revenue Y28.58 bln Y26.02 bln Operating Profit Y769.00 mln Y1.16 bln Pretax Profit Y762.00 mln Y1.16 bln Net Profit Y554 ...

Daiichi Kigenso Kagaku-Kogyo Co. Ltd. (4082.TO) Japan Year Ended March 31 GROUP 2025 2024 Revenue Y33.64 bln Y35.22 bln Operating Profit Y2.28 bln Y2.42 bln Pretax Profit Y632.00 mln Y2.94 bln Net ...

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.